8906 related articles for article (PubMed ID: 10505552)
1. CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease.
Jäger E; Jäger D; Knuth A
Cancer Metastasis Rev; 1999; 18(1):143-50. PubMed ID: 10505552
[TBL] [Abstract][Full Text] [Related]
2. Strategies for the development of vaccines to treat breast cancer.
Jäger E; Jäger D; Knuth A
Recent Results Cancer Res; 1998; 152():94-102. PubMed ID: 9928550
[TBL] [Abstract][Full Text] [Related]
3. Cancer immunotherapy in clinical oncology.
Knuth A; Jäger D; Jäger E
Cancer Chemother Pharmacol; 2000; 46 Suppl():S46-51. PubMed ID: 10950148
[TBL] [Abstract][Full Text] [Related]
4. Vaccination for malignant melanoma: recent developments.
Jäger D; Jäger E; Knuth A
Oncology; 2001; 60(1):1-7. PubMed ID: 11150901
[TBL] [Abstract][Full Text] [Related]
5. Peptide Vaccination in Clinical Oncology.
Jäger E; Jäger D; Knuth A
Onkologie; 2000 Oct; 23(5):410-415. PubMed ID: 11441234
[TBL] [Abstract][Full Text] [Related]
6. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.
Jäger D; Jäger E; Knuth A
J Clin Pathol; 2001 Sep; 54(9):669-74. PubMed ID: 11533070
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
[TBL] [Abstract][Full Text] [Related]
8. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens.
Jäeger E; Bernhard H; Romero P; Ringhoffer M; Arand M; Karbach J; Ilsemann C; Hagedorn M; Knuth A
Int J Cancer; 1996 Apr; 66(2):162-9. PubMed ID: 8603805
[TBL] [Abstract][Full Text] [Related]
9. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
10. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
[TBL] [Abstract][Full Text] [Related]
11. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
[TBL] [Abstract][Full Text] [Related]
12. Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters.
Sherritt M; Cooper L; Moss DJ; Kienzle N; Altman J; Khanna R
Int Immunol; 2001 Mar; 13(3):265-71. PubMed ID: 11222495
[TBL] [Abstract][Full Text] [Related]
13. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo.
Jäger E; Ringhoffer M; Karbach J; Arand M; Oesch F; Knuth A
Int J Cancer; 1996 May; 66(4):470-6. PubMed ID: 8635862
[TBL] [Abstract][Full Text] [Related]
14. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo.
Jäger E; Ringhoffer M; Dienes HP; Arand M; Karbach J; Jäger D; Ilsemann C; Hagedorn M; Oesch F; Knuth A
Int J Cancer; 1996 Jul; 67(1):54-62. PubMed ID: 8690525
[TBL] [Abstract][Full Text] [Related]
16. Rational development of tumour antigen-specific immunization in melanoma.
Gajewski TF; Fallarino F
Ther Immunol; 1995 Aug; 2(4):211-25. PubMed ID: 9358613
[TBL] [Abstract][Full Text] [Related]
17. The use of HLA class I tetramers to design a vaccination strategy for melanoma patients.
Palmowski M; Salio M; Dunbar RP; Cerundolo V
Immunol Rev; 2002 Oct; 188():155-63. PubMed ID: 12445289
[TBL] [Abstract][Full Text] [Related]
18. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
[TBL] [Abstract][Full Text] [Related]
19. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
20. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.
Eikawa S; Kakimi K; Isobe M; Kuzushima K; Luescher I; Ohue Y; Ikeuchi K; Uenaka A; Nishikawa H; Udono H; Oka M; Nakayama E
Int J Cancer; 2013 Jan; 132(2):345-54. PubMed ID: 22729530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
